Acetic acid--N-[(1-{N-[14-amino-1,4,7,10,13-pentahydroxy-5-(2-methylpropyl)-2,8-di(propan-2-yl)-3,6,9,12-tetraazatetradeca-3,6,9,12-tetraen-1-ylidene]-5-hydroxy-5-iminonorvalyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine (1/1) → Larazotide

HRID 2172176Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 2172176
[CH3:1][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:42])[CH3:41])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:12])[CH3:11])=[O:7])[CH3:3].CC(O)=O>O>[CH3:3][CH:2]([CH2:4][C@H:5]([NH:36][C:37]([C@@H:39]([NH:43][C:44]([CH2:46][NH:47][C:48]([CH2:50][NH2:51])=[O:49])=[O:45])[CH:40]([CH3:41])[CH3:42])=[O:38])[C:6]([NH:8][C@H:9]([C:13]([NH:15][C@H:16]([C:22]([N:24]1[C@H:28]([C:29]([NH:31][CH2:32][C:33]([OH:35])=[O:34])=[O:30])[CH2:27][CH2:26][CH2:25]1)=[O:23])[CH2:17][CH2:18][C:19]([NH2:21])=[O:20])=[O:14])[CH:10]([CH3:11])[CH3:12])=[O:7])[CH3:1]

Komponenten

3

Edukt 1

HCID 44146842Acetic acid--N-[(1-{N-[14-amino-1,4,7,10,13-pentahydroxy-5-(2-methylpropyl)-2,8-di(propan-2-yl)-3,6,9,12-tetraazatetradeca-3,6,9,12-tetraen-1-ylidene]-5-hydroxy-5-iminonorvalyl}pyrrolidin-2-yl)(hydroxy)methylidene]glycine (1/1)

Produkt 1

HCID 9810532Larazotide

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 962WaterLösungsmittel

Versuchsvorschrift

Solubilities of Larazotide acetate and the corresponding chloride salt in water were tested at 20° C. after 14 hours of vigorous stirring in the presence of residual solid. Concentrations of peptide are measured by standardized HPLC. The chloride salt is more soluble than the acetate salt.

Quellen und Nachweise

ORD-Eintrag
ord-1796805bfe664afeab2f1b5ea3d417a8
Quelldatensatz
uspto-grants-2015_06
Patentnummer
US09051349B2

Notizen zur Reaktion

Wird geladen…